AI Article Synopsis
- The study investigates montelukast as an additional treatment alongside steroids for patients with chronic nasal polyps.
- Both treatment groups showed symptom improvement, but those taking montelukast reported better relief from headaches, facial pain, and sneezing compared to the control group.
- However, the benefits of montelukast were not sustained after the treatment ended, indicating its short-term effectiveness.
Article Abstract
Objective: To examine the potential of montelukast, a leukotriene receptor antagonist, as an adjunct to oral and inhaled steroid in subjects with chronic nasal polyps.
Study Design: Prospective, randomized controlled trial.
Subjects And Methods: Thirty-eight consecutive adult patients with bilateral nasal polyps were randomized into two groups. Eighteen subjects were treated with oral prednisolone for 14 days and budenoside nasal spray for 8 weeks. Twenty subjects received similar treatment with additional oral montelukast for 8 weeks. Subjects completed a modified nasal ICSD symptom score at 8 and 12 weeks after beginning treatment and the SF-36 quality of life questionnaire at 12 weeks.
Results: Symptom scores improved in both groups after treatment. Subjects treated with montelukast reported significantly less headache (P = 0.013), facial pain (P = 0.048) and sneezing (P = 0.03) than controls. Four weeks after completing treatment, no significant differences were recorded.
Conclusion: Montelukast therapy may have clinical benefit as an adjunct to oral and inhaled steroid in chronic nasal polyposis, but effects are not maintained after cessation of treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.otohns.2008.07.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!